Use of astemizole in a large group practice.
Astemizole was released in 1988. In late 1992, a new warning label was added in response to reports of syncope and death from arrhythmia. Records of patients given new prescriptions for astemizole were reviewed to assess compliance with the warnings in a large multispecialty practice. The indication was appropriate in 89% of cases. Excessive doses were used in 4% of cases. Two percent of prescriptions were given to patients with contraindications. Only two complications were documented. Despite carrying a drug warning, astemizole continues to be used inappropriately and is a medicolegal concern. Education and drug evaluations can be used to enhance compliance and decrease the risk associated with the use of astemizole.
Craig
T J
TJ
University of Iowa, Iowa City, USA.
Greenwald
M
M
Kauffmann
V
V
Craig
J
J
D001145:Arrhythmias, Cardiac / Q000139:chemically induced*; D016589:Astemizole / Q000009:adverse effects*; D000075202:Contraindications; D004363:Drug Utilization; D006123:Group Practice; D006634:Histamine H1 Antagonists / Q000009:adverse effects*; D006801:Humans; D008508:Medication Errors; D010349:Patient Compliance; D012307:Risk Factors
D006634:Histamine H1 Antagonists; D016589:Astemizole